Literature DB >> 29897785

Heterogeneity of Treatment Effect by Baseline Risk in a Trial of Balanced Crystalloids versus Saline.

Andrew C McKown1, Luis E Huerta1, Todd W Rice1, Matthew W Semler1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29897785      PMCID： PMC6222466          DOI： 10.1164/rccm.201804-0680LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  5 in total

1.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.

Authors:  J L Vincent; R Moreno; J Takala; S Willatts; A De Mendonça; H Bruining; C K Reinhart; P M Suter; L G Thijs
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

2.  Implications of Heterogeneity of Treatment Effect for Reporting and Analysis of Randomized Trials in Critical Care.

Authors:  Theodore J Iwashyna; James F Burke; Jeremy B Sussman; Hallie C Prescott; Rodney A Hayward; Derek C Angus
Journal:  Am J Respir Crit Care Med       Date:  2015-11-01       Impact factor: 21.405

3.  Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology.

Authors:  Paul M Palevsky; Bruce A Molitoris; Mark D Okusa; Adeera Levin; Sushrut S Waikar; Ron Wald; Glenn M Chertow; Patrick T Murray; Chirag R Parikh; Andrew D Shaw; Alan S Go; Sarah G Faubel; John A Kellum; Vernon M Chinchilli; Kathleen D Liu; Alfred K Cheung; Steven D Weisbord; Lakhmir S Chawla; James S Kaufman; Prasad Devarajan; Robert M Toto; Chi-yuan Hsu; Tom Greene; Ravindra L Mehta; John B Stokes; Aliza M Thompson; B Taylor Thompson; Christof S Westenfelder; James A Tumlin; David G Warnock; Sudhir V Shah; Yining Xie; Emily G Duggan; Paul L Kimmel; Robert A Star
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-22       Impact factor: 8.237

4.  Predicting Major Adverse Kidney Events among Critically Ill Adults Using the Electronic Health Record.

Authors:  Andrew C McKown; Li Wang; Jonathan P Wanderer; Jesse Ehrenfeld; Todd W Rice; Gordon R Bernard; Matthew W Semler
Journal:  J Med Syst       Date:  2017-08-31       Impact factor: 4.460

5.  Balanced Crystalloids versus Saline in Critically Ill Adults.

Authors:  Matthew W Semler; Wesley H Self; Jonathan P Wanderer; Jesse M Ehrenfeld; Li Wang; Daniel W Byrne; Joanna L Stollings; Avinash B Kumar; Christopher G Hughes; Antonio Hernandez; Oscar D Guillamondegui; Addison K May; Liza Weavind; Jonathan D Casey; Edward D Siew; Andrew D Shaw; Gordon R Bernard; Todd W Rice
Journal:  N Engl J Med       Date:  2018-02-27       Impact factor: 91.245
  5 in total
  5 in total

Review 1.  Balanced Crystalloid Solutions.

Authors:  Matthew W Semler; John A Kellum
Journal:  Am J Respir Crit Care Med       Date:  2019-04-15       Impact factor: 21.405

Review 2.  Resuscitation fluids.

Authors:  Jonathan D Casey; Ryan M Brown; Matthew W Semler
Journal:  Curr Opin Crit Care       Date:  2018-12       Impact factor: 3.687

3.  Personalization of renal replacement therapy initiation: a secondary analysis of the AKIKI and IDEAL-ICU trials.

Authors:  Jean-Pierre Quenot; Didier Dreyfuss; Stéphane Gaudry; François Grolleau; Raphaël Porcher; Saber Barbar; David Hajage; Abderrahmane Bourredjem
Journal:  Crit Care       Date:  2022-03-21       Impact factor: 9.097

Review 4.  Coronavirus disease 2019 (COVID-19): cytokine storms, hyper-inflammatory phenotypes, and acute respiratory distress syndrome.

Authors:  Shi-Hui Lin; Yi-Si Zhao; Dai-Xing Zhou; Fa-Chun Zhou; Fang Xu
Journal:  Genes Dis       Date:  2020-06-29

5.  Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials.

Authors:  Shalini Santhakumaran; Anthony Gordon; A Toby Prevost; Cecilia O'Kane; Daniel F McAuley; Manu Shankar-Hari
Journal:  Crit Care       Date:  2019-05-03       Impact factor: 9.097
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.